AstraZeneca PLC (AZNN) - Total Assets
Based on the latest financial reports, AstraZeneca PLC (AZNN) holds total assets worth MX$114.07 Billion MXN (≈ $6.56 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AstraZeneca PLC - Total Assets Trend (2014–2025)
This chart illustrates how AstraZeneca PLC's total assets have evolved over time, based on quarterly financial data. Also see market cap of AstraZeneca PLC for the company's overall valuation and market capitalisation.
AstraZeneca PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
AstraZeneca PLC's total assets of MX$114.07 Billion consist of 25.2% current assets and 74.8% non-current assets. Review AstraZeneca PLC debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (MXN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 5.0% |
| Accounts Receivable | MX$10.24 Billion | 9.0% |
| Inventory | MX$6.56 Billion | 5.8% |
| Property, Plant & Equipment | MX$0.00 | 0.0% |
| Intangible Assets | MX$37.85 Billion | 33.2% |
| Goodwill | MX$21.24 Billion | 18.6% |
Asset Composition Trend (2014–2025)
This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AZNN live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 25.2% of total assets in 2025, a decrease from 28.5% in 2014.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 10.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, a decrease from 54.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 33.2% of total assets.
AstraZeneca PLC Competitors by Total Assets
Key competitors of AstraZeneca PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
AstraZeneca PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.94 | 0.93 | 0.87 |
| Quick Ratio | 0.72 | 0.74 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | MX$-1.89 Billion | MX$-2.04 Billion | MX$-2.78 Billion |
AstraZeneca PLC - Advanced Valuation Insights
This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.38 |
| Latest Market Cap to Assets Ratio | 2.55 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | MX$114.07 Billion |
| Market Capitalization | $290.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AstraZeneca PLC's assets at a significant premium (2.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AstraZeneca PLC's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AstraZeneca PLC (2014–2025)
The table below shows the annual total assets of AstraZeneca PLC from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | MX$114.07 Billion ≈ $6.56 Billion |
+9.65% |
| 2024-12-31 | MX$104.03 Billion ≈ $5.99 Billion |
+2.88% |
| 2023-12-31 | MX$101.12 Billion ≈ $5.82 Billion |
+4.80% |
| 2022-12-31 | MX$96.48 Billion ≈ $5.55 Billion |
-8.43% |
| 2021-12-31 | MX$105.36 Billion ≈ $6.06 Billion |
+57.90% |
| 2020-12-31 | MX$66.73 Billion ≈ $3.84 Billion |
+8.72% |
| 2019-12-31 | MX$61.38 Billion ≈ $3.53 Billion |
+1.20% |
| 2018-12-31 | MX$60.65 Billion ≈ $3.49 Billion |
-4.27% |
| 2017-12-31 | MX$63.35 Billion ≈ $3.65 Billion |
+1.32% |
| 2016-12-31 | MX$62.53 Billion ≈ $3.60 Billion |
+4.11% |
| 2015-12-31 | MX$60.06 Billion ≈ $3.46 Billion |
+2.49% |
| 2014-12-31 | MX$58.59 Billion ≈ $3.37 Billion |
-- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more